Comparison Between Effect of Vildagliptin And Linagliptin on Glycaemic Control, Renal Function, Liver Function And Lipid Profile in Patients of T2DM Inadequately Controlled With Combination of Metformin And Glimepiride

Objective: Type 2 diabetes mellitus(T2DM) is a progressive disease, pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long time. In this study two dipeptidyl peptidase-4 inhibitors vildagliptin and linagliptin was used for comparative study as add on therapy in type 2 diabetes mellitus patients inadequately controlled with dual combination metformin and glimepiride. Material And Methods: The study was a prospective, randomized, open label comparison. A total of 234 T2 DM patients who failed to achieve glycaemic control with metformin and glimepiride were recruited to receive vildagliptin or linagliptin as an additional drug. Patients were divided into two groups. One group received vildagliptin and second group received linagliptin as an add on drug with metformin and glimepiride. Fasting and postprandial plasma glucose, glycosylated hemoglobin (HbA1c), lipid profile, liver function, renal function were monitored before and 24 weeks after treatment. Results: Both the groups were well matched in terms of age, weight, clinical finding and laboratory values. At 24 weeks in both groups, the reduction of blood sugar and glycated hemoglobin were significant and comparable. Effects of linagliptin on renal function and hepatic function was found better than vildagliptin. Significant improvement was observed in low density lipoprotein (LDL-C) levels in patients of linagliptin group. Conclusion: Both vidagliptin and linagliptin significantly lower blood sugar but linagliptin is better than vildagliptin for renal function, hepatic function and lipid profile